## Zofia T Bilinska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7875461/publications.pdf

Version: 2024-02-01

304743 118850 4,292 65 22 62 h-index citations g-index papers 67 67 67 5794 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal, 2007, 29, 270-276.	2.2	2,280
2	Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2010, 31, 2715-2726.	2.2	408
3	Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. European Heart Journal, 2008, 29, 1350-1358.	2.2	211
4	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal, 2018, 39, 1784-1793.	2.2	94
5	Dilated Cardiomyopathy DueÂtoÂBLC2-Associated AthanogeneÂ3Â(BAG3)ÂMutations. Journal of the American College of Cardiology, 2018, 72, 2471-2481.	2.8	93
6	Does p.Q247X in TRIM63 Cause Human Hypertrophic Cardiomyopathy?. Circulation Research, 2014, 114, e2-5.	4.5	88
7	In vivo and in vitro examination of the functional significances of novel lamin gene mutations in heart failure patients. Journal of Medical Genetics, 2005, 42, 639-647.	3.2	87
8	The BAG3 gene variants in Polish patients with dilated cardiomyopathy: four novel mutations and a genotype-phenotype correlation. Journal of Translational Medicine, 2014, 12, 192.	4.4	81
9	Genetic and ultrastructural studies in dilated cardiomyopathy patients: a large deletion in the lamin A/C gene is associated with cardiomyocyte nuclear envelope disruption. Basic Research in Cardiology, 2010, 105, 365-377.	5.9	79
10	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the <i>TTN</i> Gene. Circulation: Heart Failure, 2020, 13, e006832.	3.9	75
11	Determinants of prognosis in nonischemic dilated cardiomyopathy. Journal of Cardiac Failure, 1996, 2, 77-85.	1.7	64
12	Titin Truncating Variants in Dilated Cardiomyopathy – Prevalence and Genotype-Phenotype Correlations. PLoS ONE, 2017, 12, e0169007.	2.5	63
13	Lamin A/C mutations in dilated cardiomyopathy. Cardiology Journal, 2014, 21, 331-342.	1.2	53
14	Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. European Heart Journal, 2021, 42, 2000-2011.	2.2	49
15	Next-generation sequencing for diagnosis of thoracic aortic aneurysms and dissections: diagnostic yield, novel mutations and genotype phenotype correlations. Journal of Translational Medicine, 2016, 14, 115.	4.4	47
16	Autophagy in transition from hypertrophic cardiomyopathy to heart failure. Journal of Electron Microscopy, 2010, 59, 181-183.	0.9	40
17	Evidence for troponin C ( <i>TNNC1</i> ) as a gene for autosomal recessive restrictive cardiomyopathy with fatal outcome in infancy. American Journal of Medical Genetics, Part A, 2016, 170, 3241-3248.	1.2	37
18	Homozygous truncating mutation in NRAP gene identified by whole exome sequencing in a patient with dilated cardiomyopathy. Scientific Reports, 2017, 7, 3362.	3.3	30

#	Article	IF	CITATIONS
19	A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations. BMC Medical Genetics, 2015, 16, 21.	2.1	28
20	Specific contribution of lamin A and lamin C in the development of laminopathies. Experimental Cell Research, 2008, 314, 2362-2375.	2.6	25
21	Variants of the Lamin A/C (LMNA) Gene in Non-Valvular Atrial Fibrillation Patients. Molecular Diagnosis and Therapy, 2012, 16, 99-107.	3.8	24
22	Coronary Computed Tomographic Angiography for Prediction of Procedural and Intermediate Outcome of Bypass Grafting to Left Anterior Descending Artery Occlusion With Failed Visualization on Conventional Angiography. American Journal of Cardiology, 2012, 109, 1722-1728.	1.6	23
23	Rapid and effective response of the R222Q SCN5A to quinidine treatment in a patient with Purkinje-related ventricular arrhythmia and familial dilated cardiomyopathy: a case report. BMC Medical Genetics, 2018, 19, 94.	2.1	23
24	Obliteration of cardiomyocyte nuclear architecture in a patient with LMNA gene mutation. Journal of the Neurological Sciences, 2008, 271, 91-96.	0.6	22
25	ESC EORP Cardiomyopathy Registry: realâ€life practice of genetic counselling and testing in adult cardiomyopathy patients. ESC Heart Failure, 2020, 7, 3013-3021.	3.1	19
26	Variable clinical presentation of glycogen storage disease type IV: from severe hepatosplenomegaly to cardiac insufficiency. Some discrepancies in genetic and biochemical abnormalities. Archives of Medical Science, 2018, 1, 237-247.	0.9	17
27	A combination of quinidine/mexiletine reduces arrhythmia in dilated cardiomyopathy in two patients with R814W <i>SCN5A</i> mutation. ESC Heart Failure, 2020, 7, 4326-4335.	3.1	13
28	A new c.1621 C>G, p.R541G lamin A/C mutation in a family with DCM and regional wall motion abnormalities (akinesis/dyskinesis): genotype–phenotype correlation. Journal of Human Genetics, 2011, 56, 83-86.	2.3	12
29	Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol. Pharmacogenetics and Genomics, 2013, 23, 611-618.	1.5	12
30	Analysis of De Novo Mutations in Sporadic Cardiomyopathies Emphasizes Their Clinical Relevance and Points to Novel Candidate Genes. Journal of Clinical Medicine, 2020, 9, 370.	2.4	12
31	Restrictive cardiomyopathy due to novel desmin gene mutation. Kardiologia Polska, 2017, 75, 723-723.	0.6	12
32	Usefulness of 1H MR spectroscopy in the evaluation of myocardial metabolism in patients with dilated idiopathic cardiomyopathy. Academic Radiology, 2003, 10, 1187-1192.	2.5	11
33	LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies. BMC Medical Genetics, 2013, 14, 55.	2.1	11
34	Dilated cardiomyopathy with profound segmental wall motion abnormalities and ventricular arrhythmia caused by the R541C mutation in the LMNA gene. International Journal of Cardiology, 2010, 144, e51-e53.	1.7	10
35	Quantification of mitral regurgitation in patients with hypertrophic cardiomyopathy using aortic and pulmonary flow data: impacts of left ventricular outflow tract obstruction and different left ventricular segmentation methods. Journal of Cardiovascular Magnetic Resonance, 2017, 19, 105.	3.3	10
36	Impact of cardiac magnetic resonance on the diagnosis of hypertrophic cardiomyopathy - a 10-year experience with over 1000 patients. European Radiology, 2021, 31, 1194-1205.	4.5	10

#	Article	IF	CITATIONS
37	Platelet reactivity on aspirin, clopidogrel and abciximab in patients with acute coronary syndromes and reduced estimated glomerular filtration rate. Thrombosis Research, 2010, 125, 67-71.	1.7	9
38	Can Circulating Cardiac Biomarkers Be Helpful in the Assessment of LMNA Mutation Carriers?. Journal of Clinical Medicine, 2020, 9, 1443.	2.4	9
39	Organ-specific cardiac autoantibodies in dilated cardiomyopathy. European Heart Journal, 1995, 16, 1907-1911.	2.2	8
40	Sudden cardiac arrest in patients without overt heart disease: limited value of next generation sequencing. Polish Archives of Internal Medicine, 2018, 128, 721-730.	0.4	8
41	Dilated cardiomyopathy caused by LMNA mutations. Clinical and morphological studies. Kardiologia Polska, 2006, 64, 812-9; discussion 820-1.	0.6	8
42	Cumulative incidence of coronary lesions with vulnerable characteristics in patients with stable angina pectoris: an intravascular ultrasound and angiographic study. International Journal of Cardiology, 2005, 102, 201-206.	1.7	7
43	Severe Course of Peripartum Cardiomyopathy and Subsequent Recovery in a Patient with a Novel TTN Gene-Truncating Mutation. American Journal of Case Reports, 2018, 19, 820-824.	0.8	7
44	Increased frequency of organâ€specific cardiac antibodies in healthy relatives of patients with dilated cardiomyopathy: Evidence for autoimmunity in polish families. Clinical Cardiology, 1996, 19, 794-798.	1.8	6
45	Unexpected eosinophilic myocarditis in a young woman with rapidly progressive dilated cardiomyopathy. International Journal of Cardiology, 2002, 86, 295-297.	1.7	6
46	Protein Kinase C Alpha Cellular Distribution, Activity, and Proximity with Lamin A/C in Striated Muscle Laminopathies. Cells, 2020, 9, 2388.	4.1	6
47	Lamin missense mutations—the spectrum of phenotype variability is increasing. European Journal of Heart Failure, 2018, 20, 1413-1416.	7.1	5
48	Tripeptidyl Peptidase 1 (TPP1) Deficiency in a 36-Year-Old Patient with Cerebellar-Extrapyramidal Syndrome and Dilated Cardiomyopathy. Life, 2022, 12, 3.	2.4	5
49	Sudden cardiac death risk in hypertrophic cardiomyopathy: comparison between echocardiography and magnetic resonance imaging. Scientific Reports, 2021, 11, 7146.	3.3	4
50	Good performance of the criteria of American College of Medical Genetics and Genomics/Association for Molecular Pathology in prediction of pathogenicity of genetic variants causing thoracic aortic aneurysms and dissections. Journal of Translational Medicine, 2022, 20, 42.	4.4	4
51	Left ventricular enlargement is common in relatives of patients with dilated cardiomyopathy. Journal of Cardiac Failure, 1995, 1, 347-353.	1.7	3
52	Baseline Clinical Characteristics and Midterm Prognosis of STEâ€ACS and NSTEâ€ACS Patients with Normal Coronary Arteries. Annals of Noninvasive Electrocardiology, 2009, 14, 4-12.	1.1	3
53	The protective effect of influenza vaccination on the clinical course of coronary disease in patients with acute coronary syndromes treated by primary PCI $\hat{a} \in \text{``areport from FLUCAD study. Postepy W}$ Kardiologii Interwencyjnej, 2010, 1, 6-11.	0.2	3
54	A different background of arrhythmia in siblings with a positive family history of sudden death at young age. Annals of Noninvasive Electrocardiology, 2020, 25, e12707.	1,1	3

#	Article	IF	CITATIONS
55	A Recurrent Exertional Syncope and Sudden Cardiac Arrest in a Young Athlete with Known Pathogenic p.Arg420Gln Variant in the RYR2 Gene. Diagnostics, 2020, 10, 435.	2.6	3
56	Titin-Related Dilated Cardiomyopathy: The Clinical Trajectory and the Role of Circulating Biomarkers in the Clinical Assessment. Diagnostics, 2022, 12, 13.	2.6	3
57	A Novel DSP Truncating Variant in a Family with Episodic Myocardial Injury in the Course of Arrhythmogenic Cardiomyopathy—A Possible Role of a Low Penetrance NLRP3 Variant. Diagnostics, 2020, 10, 955.	2.6	2
58	Novel truncating desmoplakin mutation as a potential cause of sudden cardiac death in a family. Polish Archives of Internal Medicine, 2016, 126, 704-707.	0.4	2
59	Autosomal recessive, familial, isolated dilated cardiomyopathy due to compound desmoplakin gene mutations. Polish Archives of Internal Medicine, 2018, 128, 785-787.	0.4	2
60	s A fatal outcome of thoracic aortic aneurysm in a male patient with bicuspid aortic valve. Postepy W Kardiologii Interwencyjnej, 2013, 3, 265-271.	0.2	1
61	Therapeutic challenges and management of heart failure during pregnancy (part I). Medical Science Monitor, 2012, 18, CQ5-CQ7.	1.1	1
62	Familial dilated cardiomyopathy: evidence for clinical and immunogenetic heterogeneity. Medical Science Monitor, 2003, 9, CR167-74.	1.1	1
63	Clinical Applications for Next Generation Sequencing in Cardiology. , 2016, , 189-215.		O
64	Therapeutic challenges and management of heart failure during pregnancy (part 2). Medical Science Monitor, 2012, 18, CQ9-CQ13.	1.1	0
65	A new missense mutation, p.Arg719Leu, of the beta-myosin heavy chain gene in a patient with familial hypertrophic cardiomyopathy. Minerva Cardiology and Angiology, 2016, 65, 96-102.	0.7	O